Find and explore trending articles from around the web in a clutter-free reading mode.
cnbc.com • Finance • World
JPMorgan Chase analyst Chris Schott upgraded Teva Pharmaceuticals stock to overweight due to the company's successful cost-reduction plan, predicting significant margin improvements and future growth.